Product Description
BMS-986263 is a lipid nanoparticle delivering small interfering RNA designed to degrade HSP47 mRNA, for the treatment of advanced fibrosis. (Sourced from: https://aasldpubs.onlinelibrary.wiley.com/doi/10.1002/hep.32181)
Mechanisms of Action: HSP47 Antagonist
Novel Mechanism: Yes
Modality: Nucleic Acid
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Bristol-Myers Squibb
Company Location: NEW YORK NY 10016
Company CEO: Giovanni Caforio
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Belgium, Brazil, Canada, France, Germany, Israel, Italy, Japan, Korea, Spain, Switzerland, Taiwan, United Kingdom, United States, Unknown Location
Active Clinical Trial Count: 5
Highest Development Phases
Phase 2: Hepatitis, Alcoholic|Idiopathic Pulmonary Fibrosis|Liver Cirrhosis|Non-alcoholic Steatohepatitis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 2019-003932-22 | P2 |
Active, not recruiting |
Liver Cirrhosis|Non-alcoholic Steatohepatitis|Hepatitis, Alcoholic |
2026-09-04 |
|
| jRCT2011200024 | P2 |
Recruiting |
Liver Cirrhosis|Non-alcoholic Steatohepatitis |
2024-02-29 |
|
| jRCT2080225045 | P2 |
Completed |
Idiopathic Pulmonary Fibrosis |
2023-12-31 |
|
| JUNIPER | P2 |
Completed |
Idiopathic Pulmonary Fibrosis |
2022-08-24 |